Figure S1. Effect of FBDS on RAW264.7 and BMDMs viability, and identification of BMDMs. RAW264.7 cells and BMDMs were incubated with blank serum or FBDS (10%) for 24 h, followed by LPS stimulation (100 ng/ml) for 8 h. (A) Cell viability of RAW264.7 and BMDMs. (B) BMDMs identified by flow cytometry using F4/80 and CD11b antibodies. Data are representative of three independent experiments (mean ± standard deviation). FBDS, Feibi decoction-medicated serum; BMDMs, bone marrow derived macrophages; LPS, lipopolysaccharide.
Figure S2. NF-κB, Smad2/Smad3 activation and TGF-β1, CHI3L1 expression levels are suppressed by FBDS treatment in RAW264.7 cells. RAW264.7 cells were incubated with blank serum or FBDS (10%) for 24 h, followed by LPS stimulation (100 ng/ml) for 8 h. (A) Phosphorylation of p65 and IKKβ and (B) Smad2 and Smad3 were examined by western blot assay. (C) The protein levels of TGF-β1 and CHI3L1. Data are representative of three independent experiments. TGF, transforming growth factor; CHI3L1, chitinase-3-like protein 1; FBDS, Feibi decoction-medicated serum; LPS, lipopolysaccharide; p-, phosphorylated.